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1. Introduction
   The therapeutic effectiveness of any drug may obtained 
from plant, animal, sea or synthetic which depends upon the 
ability of the dosage form to deliver the medicament to its site 
of action at a rate and amount sufficient to elicit the desired 
pharmacological response. This attribute of the dosage form is 
referred to as physiologic availability, biological availability or 
simply bioavailability[1]. For most drugs, the pharmacological 
response can be related directly to the plasma levels. Thus, 
the term bioavailability is defined as the rate and extent 
(amount) of absorption of unchanged drug from its dosage form. 
Sometimes, a fast absorption is desired when a rapid onset of 
action is needed in the treatment of acute conditions such as 
asthma attack, pain etc. A slow rate of absorption is needed 
when the objective is to prolong the duration of action or to 
overcome the adverse effect and extent of absorption which is 
also significant in the treatment of chronic conditions such as 
hypertension, epilepsy, etc. These can be achieved by altering 
the physicochemical properties of the drug and characteristics 
of the dosage form[1]. 
   Phytomedicine have been serving as a crucial source of 
drugs since ancient times. Today, about 50% of useful drugs is 
obtained from natural sources[2]. The usage of phytomedicine 
has been increased due to their better therapeutic activity 
and less side effects as compared to the allopathic medicines. 
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Phytochemical and pharmacological investigation have been 
done extensively and well established. Phytomedicines shows 
impressive in-vitro activity but less in-vivo efficacy due to their 
poor water solubility, lipophilicity and inappropriate molecular 
size resulting in poor absorption and hence poor systemic 
availability. A better understanding of the biopharmaceutics 
and pharmacokinetics of phytomedicine can also help in 
designing rational dosage regimens[3].
   Nanotechnology is on the threshold of providing a host of 
new materials and approaches in revolutionizing medical and 
pharmaceutical field. Several areas of medical care are already 
profiting from the advantage of nanotechnology[4]. 
   The use of nanotechnology for treatment, identification, 
monitoring, and managing biological systems have recently 
been referred to as nanomedicine. In the herbal formulation 
research, incorporating the nano-based formulation has a 
great number of advantages for phytomedicine, including 
improvement of solubility and bioavailability, safeguard 
from toxicity, enhancement of pharmacological activity, 
improvement of stability, increase in tissue macrophages 
distribution, sustained delivery, protection from physical and 
chemical degradation, etc.[5]. Thus nano phytomedicine have 
a prospective future for improving the activity and overcoming 
problems associated with herbal drugs (Figure 1).
Improving bioavailability
Sustained delivery Enhancement of stabilityEnhancing pharmacological activity
Protection from physical and  
chemical degradation
Improving tissue macrophages 
distribution
Protection from toxicity
Nanophytomedicine
Enhancement of solubility
Figure 1. Applications of nanotechnology based phytomedicine formulation. 
2. Problems encountered in phytomedicine product 
development
   Mostly, phytomedicines are called as secondary metabolites 
and these metabolites are being chemically isolated 
and identified. The production of active constituents of 
phytomedince represents a lot of challenges[6]. These secondary 
metabolites which are present in plant are very low and their 
active constituents vary depending on a number of factors, 
such as botanical species, used chemotypes, the anatomical 
part of the plant used (seed, flower, root, leaf, and so on) and 
also storage, sun, humidity, type of ground, time of harvest and 
geographic area[7]. Phytomedicine screening from the plant 
is another challenge, and even though the high throughput 
methods are normally employed in the screening of drugs in 
pharmaceutical field, it is not suitable for the phytomedicine as 
crude extracts contain numerous drug compounds. Moreover, 
some active constituents present in the plant gave false 
information when screening by high throughput techniques[2]. 
In addition to this, identification, isolation of active constituents 
and fractionation process also takes weeks or even months 
and active ingredient supply is also another challenge, which 
needs several hundreds of grams for preclinical development 
depending upon the utility.
   Many phytomedicine and extracts of plant despite of their 
surprising potential in-vitro finding, exhibit least or no 
significant in-vivo activity due to their poor solubility, poor 
lipid solubility and improper size result in poor absorption and 
bioavailability. Another problem is their structural instability in 
biological milieu, premature drug loss through rapid clearance 
and biotransformation and some plant extracts are destroyed in 
gastric juice during gastric emptying when administered orally.
3. Various nanotechnologies approaches for enhancing 
the bioavailability and bioactivity of phytomedicine
   Phytomedicines are attracting more popular in the current 
world for their application to cure a variety of diseases with 
less toxic effects and high therapeutic property. However some 
limitations of phytomedicine are discussed in the previous 
section. Nanotechnology can serve as an efficient tool in 
eradicating the limitations stated above. By reducing the size 
of the phytomedicine into nano phytomedicine and modifying 
surface properties of phytomedicine, the aqueous solubility and 
permeability through biological membrane. Various novel drug 
delivery systems such as liposomes, niosomes, nanospheres 
and phytosomes have been reported to have the ablility of 
delivering herbal drugs. Incorporation of herbal drugs in the 
delivery system also gives aid to increase in solubility, enhance 
stability, protect from toxicity, enhance pharmacological 
activity, improve tissue macrophage distribution, sustain 
delivery and protect from physical and chemical degradation[8]. 
Moreover, to use nanotechnology, it may be likely to accomplish 
(1) enhanced delivery of poorly water-soluble phytomedicine; (2) 
targeted delivery of phytomedicine in a cell- or tissue-specific 
way; (3) transcytosis of phytomedicine across tight epithelial 
and endothelial barriers; (4) delivery of large macromolecule 
phytomedicine to intracellular sites of action; (5) co-delivery 
of two or more phytomedicines or therapeutic modality for 
combination therapy; (6) observation of sites of drug delivery by 
incorporating phytomedicine with imaging modalities[9,10]. 
3.1. Reducing the size of the phytomedicine into nanophytomedicine
   Most of the phytomedicine formulation is administered orally 
because of patient convenience and manufacturing advantages 
compared with other dosage forms. For the orally administered 
drug, there are two critical slower rate-determining steps (RDSs) 
in the absorption. First is the rate of dissolution and the rate 
of drug permeation through the membrane is an another step. 
Dissolution is the RDS for hydrophobic in poorly aqueous soluble 
drugs and absorption of such drugs is said to be dissolution rate 
limited. If the drug is hydrophilic with high aqueous solubility, 
then dissolution will be rapid and RDS in the absorption of such 
drugs will be the rate of permeation through the biomembrane. 
That is said to be permeation rate limited or transmembrane 
rate limited (Figure 2).
   A well formulated nanophytomedicine prepared through 
various routes of synthesis, by virtue of their size, enhances 
the dissolution, absorption and bioavailability of drugs while 
reduces in the dose. Cuscuta chinensis (C. chinensis) is a Chinese 
drug containing flavonoids and lignins as active medicament, 
which is poor aqueous solubility and poor absorption upon oral 
administration. The nano sized C. chinensis were prepared by 
a nanosuspension method for hepatoprotective and antioxidant 
effects after oral administration. The 25 and 50 mg/kg oral 
doses showed similar activity as that of 125 and 250 mg/kg 
ethanolic extract of C. chinensis, five fold reduction in dose 
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was observed with nano sized C. chinensis[11]. Su YL, et al., 
2008[12] investigated Radix salvia nanoparticles prepared by 
spray drying method for coronary heart disease, angina pectoris 
and myocardial infarction, nanosized Radix salvia showing 
improved bioavailability. The reduction of the size of the 
phytomedicine improves aqueous solubility. Generally water 
soluble drugs whose size smaller than the diameter of the pore 
of the biomembrane can penetrate easily. The driving force is 
constituted by the hydrostatic pressure or the osmotic difference 
across the biomembrane due to which bulk flow of water 
along with small solid molecules occur through such aqueous 
channels.
3.2. Modification of surface properties
   Surface modification can be achieved by surface coating with 
hydrophilic, stabilizing, mucoadhesive polymers/surfactants or 
by the production of biodegradable copolymers with hydrophilic 
segments[13]. These modifications change the zeta potential 
of nanoparticles, hydrophobicity, stability, mucoadhesive 
properties and protein adsorption on their surface. Surface 
properties of particles and size have a significant impact on 
particle uptake (Figure 3).
Figure 3. Use of surface modification in phytomedicine drug delivery.
Membrane passing properties
Protective properties Mucoadhesive properties
Permeation enhancing properties
Surface modification
   The membrane passing and permeation can be increased by 
using the surface modification[14-16]. Intestinal transit results 
in reducing the phytomedicine residence time and limits the 
bioavailability of herbal drugs. One possible way to increase 
the bioavailability of phytomedicine which has low mucosal 
absorptive properties and to increase its residence time at 
mucosal or epithelial level is by incorporating phytomedicine 
in micro or nanoparticles. When a suspension of micro or nano 
phytomedicine is administered orally, they diffuse into the 
gastrointestinal medium and encounter the mucus at which 
they could adhere.
   One of the big impediments of oral administration of 
phytomedicine is their lack of stability in the gastrointestinal 
tract. The surface-modified micro or nano phytomedicine can 
be used as an efficient strategy to circumvent this problem. 
The poly(lactic-co-glycolic) acid (PLGA) microspheres with 
chitosan[17], and PEGylated PLGA-based nanoparticles were 
used to modify the properties of formulations[18].
3.3. Attaching the polymers with phytomedicine
   A variety of polymers are being utilized in these and other 
biomedical applications; for example, polyvinyl chloride 
used in the manufacture of cardiac catheters, surgical tapes, 
artificial hearts, blood pumps and artificial limbs[19-22]. By 
modifying polymer surfaces one may achieve a number of 
desirable properties ranging from blood clotting prevention 
to controllable drug release, and other applications, while 
maintaining useful bulk polymer properties. Each particle is a 
matrix of the drug dispersed in the polymer and drug is released 
as a first order process. The polymers used for the fabrication 
of the microspheres are biodegradable or non biodegradable. 
Various polymers have been used for the fabrication of these 
microparticulate carriers such as albumin, gelatin, modified 
starch, polypropylene, dextran, polylactic acid and poly 
lactide-co-glycolide etc. The drug release is controlled by the 
dissolution and degradation of the matrix (Figure 4).
Figure 4. Release of phytomedicine from the polymer scaffold.
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   R Garg, et al., 2010[23] encapsulated the phytomedicine, 
silymarin with the eudragit S 100 (ES100) and eudragit RL (ERL) 
polymers in order to increase the bioavailability. Silymarin 
is poorly soluble in water, therefore, an acidic medium is 
essential for its dissolution. R Garg, et al., 2010[23] developed 
gastroretentive floating microspheres of silymarin which 
following oral administration would exhibit prolonged gastric 
residence time, hence they would increase the bioavailability 
of the drug. Silymarin releases from the formulations followed 
zero order kinetics and the mechanism of drug release was 
diffusion-controlled. You J, et al., 2006[24] prepared the 
sustained-release formulation with self-emulsifying capability 
containing zedoary turmeric oil which were prepared by 
the quasi-emulsion-solvent-diffusion method. The plasma 
concentration-time profiles with improved sustained-release 
characteristics were achieved after oral administration of the 
formulation with a bioavailability of 135.6% with respect to the 
conventional self-emulsifying formulation (a good strategy for 
improving the bioavailability of an oily drug). In conclusion, 
the sustained-release formulation with self-emulsifying 
capability containing zedoary turmeric oil has an improved 
oral bioavailability. Chao P, et al., 2010[25] investigated the 
pulmonary targeting microparticulate camptothecin delivery 
system for anticancer evaluation in a rat orthotopic lung cancer 
model. The study shows that microparticulate is able to achieve 
effective local lung and low systemic drug concentrations at a 
dose which was 10 times lower than systemically administered 
drug resulting in a significant improvement in anticancer 
efficacy in an orthotopic rat model of lung cancer.
Figure 2. The two rate-determining steps in the absorption of orally administered phytomedicine formulation.
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3.4. Nano carriers for phytomedicine
   The main goals in designing nanoparticles as a delivery 
system is to manage particle size, surface properties and release 
of bioactive agents in order to accomplish the site-specific 
action of the drug at the therapeutically optimal rate and dose 
regimen. There are certain advantages of using nanoparticles 
in phytomedicine drug delivery system include, (1) particle 
size and surface characteristics of the nanoparticles can be 
modified easily for both passive and active target; (2) controlled 
release and degradation can be manipulated easily with matrix 
constituents, so drug can be incorporated into the system 
free from chemical reaction and with high loading of drug; (3) 
surface properties of the nanoparticles helps to achieve site 
specific delivery by attaching target ligands to the surface of the 
particles. 
   The different method can be used for nano phytomedicine 
formulation such as high pressure homogenization method[5,26], 
complex coacervation method[5], co-precipitation[5], salting 
out method[5], nanoprecipitation or solvent displacement 
method[5,27], solvent emulsification-diffusion method[5], 
supercritical fluid method[5,28] and self assembly method[5] 
(Figure 5). Different types of nanophytopharmaceuticals such 
as polymeric nanoparticles, solid lipid nanoparticles, magnetic 
nanoparticles, metal and inorganic nanoparticles, quantum 
dots, polymeric micelles, phospholipid micelles, colloidal 
nano-liposomes, dendrimers can be prepared with the help of 
the methods stated above (Figure 6).
Figure 5. Common techniques used in nanophytomedicine formulation.
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Figure 6. Various types of nanophytopharmaceuticals.
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   A number of studies have been carried out to elucidate 
different nano carriers for phytomedicine delivery. Recently, 
Deepa V, et al., 2012[29] investigated nano emulsified ethanolic 
extract of Phyllanthus amarus Schum & Thonn ameliorated 
which was poorly water soluble. Their study illustrated that the 
nanophytomedcine formulation showed better hepatoprotective 
activity than Phyllanthus amarus Schum (100 mg/kg body 
weight) and also repeated dose oral toxicity proved to be safe.
   Zhang J, et al . ,  2012[30]  developed novel Panax 
notoginsenoside-loaded core-shell hybrid liposomal 
vesicles (PNS-HLV) were developed to resolve the restricted 
bioavailability of PNS and to enhance its protective effects 
in-vivo on oral administration. They compared the effect 
of PNS-HLV on global cerebral ischemia/reperfusion and 
acute myocardial ischemia injury with those of PNS solution, 
conventional PNS-loaded nanoparticles, and liposomes. They 
concluded that HLV had promising prospects for improving free 
drug bioactivity on oral administration.
   Li Z, et al., 2012[31] evaluated the effect of celastrol 
nanoparticles on retinoblastoma and the potential mechanisms 
involved. Celastrol is a Chinese herbal medicine which is poorly 
soluble in water and inhibits the growth of retinoblastoma in a 
mouse xenograft model by inducing apoptosis in SO-Rb 50 cells, 
which may be related to the increased Bax/Bcl-2 ratio and the 
inhibition of NF-κB. Celastrol nanoparticles may represent a 
potential alternative treatment for retinoblastoma.
   Shi F, et al., 2012[32] prepared solid lipid nanoparticles (SLNs) 
for the oral delivery of frankincense and myrrh essential oils by 
a high-pressure homogenization method using Compritol 888 
ATO as the solid lipid and soybean lecithin and Tween 80 as the 
surfactants. They concluded that SLNs could be used as drug 
carriers for hydrophobic oil drugs extracted from traditional 
Chinese medicines.
   Kundu P, et al., 2012[33] investigated antiglioma activity 
of curcumin-loaded lipid nanoparticles and its enhanced 
bioavailability in brain tissue for effective glioblastoma therapy. 
The greatest challenge in the administration of curcumin stems 
from its low bioavailability and high rate of metabolism. They 
demonstrated that curcumin-loaded nanoparticles inhibited 
cellular proliferation, migration and invasion along with a 
higher percentage of cell cycle arrest and telomerase inhibition, 
thus leading to a greater percentage of apoptotic cell death in 
glioma cells compared with native curcumin. An in-vivo study 
demonstrated an enhanced bioavailability of curcumin in blood 
serum and brain tissue when being delivered by curcumin-
loaded glyceryl monooleate nanoparticles compared with native 
curcumin in a rat model. Thus, curcumin-loaded nanoparticles 
can be used as an effective delivery system to overcome the 
challenges of drug delivery to the brain, providing a new 
approach to glioblastoma therapy.
   Han L, et al., 2012[34] prepared an injectable nanoparticulate 
system based on a monomethoxy (polyethylene glycol)-poly 
(lactide-co-glycolide)-monomethoxy (polyethyleneglycol)
(PELGE) for co-encapsulation and sustained release of four 
active components (ginkgolides A, B, C and bilobalide) in 
Ginkgo biloba extract. Sustained and synchronized release of 
the four components from PELGE nanoparticles was observed 
both in vitro and in vivo, which was mainly contributed to 
the long circulation of PEGylated nanoparticles and the slow 
degradation of PLGA. The half-life time of the four terpenoid 
compounds was also significantly improved by incorporating 
into PELGE nanoparticles. The results indicate that a PELGE 
nanoparticle is a promising carrier system for sustained and 
synchronized release of herbal medicines containing multiple 
components.
   Zhang J, et al., 2011[35] investigated the potential of oral 
and pulmonary nanocrystal to enhance the bioavailability 
of baicalein, a bioactive flavonoid isolated from the root of 
Scutellaria baicalensis Georgi. The baicalein nanocrystal was 
prepared by anti-solvent recrystallization followed by high 
pressure homogenization. They concluded that the mean 
relative bioavailability of oral baicalein nanocrystal was 
1.67-fold that of oral baicalein crystal. The pulmonary baicalein 
nanocrystal had rapid and extensive absorption and had almost 
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identical pharmacokinetic parameters to intravenous baicalein 
injection.
   Chang LC, et al., 2011[36] described an optimal method for 
preparing tanshinone IIA nanoemulsions (TA-NEs) to solve 
the problems of tanshinone IIA poor solubility in water and 
insufficient dissolution rate. Optimization of the method for 
preparing nanoemulsions of lipid soluble TA by emulsification/
high pressure homogenization was carried out with a 2 (3) 
factorial design, using Tween 80, lecithin and water content 
as independent variables. TA-NE-F4 particles were spherical 
and intact, with a mean particle size of 95.6 nm and a high 
entrapment efficiency of 99.3%. TA-NE-F4 showed a fast 
dissolution rate of 80% in 10 min and 100% in 20 min. The 
cytotoxicity of TA-NE-F4 against T24 human bladder cancer 
cells was 103.4-fold greater than TA alone in both a time- and 
a dose-dependent manner. Overall, they described a feasible 
method for preparing TA-NEs that exhibited potent cytotoxicity.
   Zhang H, et al., 2011[37] prepared and studied the in vitro 
release characteristics of curcumin in nano suspensions by the 
solvent evaporation method. The method described to prepare 
curcumin albumin nano suspensions is simple. It might be a 
novel vehicle potentially for a nanoparticle drug delivery system 
of curcumin.
   Hu L, et al., 2010[38] investigated SLNs prepared by an 
ultrasonic and high-pressure homogenization method to 
improve the oral bioavailability of the poorly water-soluble 
drug cryptotanshinone. The particle size and distribution, drug 
loading capacity, drug entrapment efficiency, zeta potential and 
long-term physical stability of the SLNs were characterized in 
detail. These results indicate that cryptotanshinone absorption 
is enhanced significantly by employing SLN formulations, and 
SLNs represent a powerful approach for improving the oral 
absorption of poorly soluble drugs.
   Zhao XL, et al., 2010[39] studied the preparation and 
characteristics of zedoary turmeric oil, a traditional Chinese 
oily medicine, loaded with nanostructured lipid carriers. The 
authors suggested that the presented nanostructured lipid 
carrier system might be a promising intravenous dosage form of 
water-insoluble oily drugs.
   Sutthanut K, et al., 2009[40] formulated extracts of Kaempferia 
parviflora (K. parviflora) in solid lipid nanoparticles (SLNs) 
in order to enhance their transdermal permeability. The K. 
parviflora extracts were entrapped within SLNs by adding them 
to a melted mixture of oils, surfactants and PEGylated agents 
and subsequently forming an oil-in-water microemulsion at an 
elevated temperature. Cooling of this microemulsion resulted 
in the formation of SLNs. The formulation with the optimum 
properties was composed of stearyl alcohol as the nanoparticle 
matrix and tocopheryl polyethylene glycol succinate as the 
surfactant. Particle sizes of 82-108 nm were obtained with 
entrapment efficiencies as high as 87%. The amount of total K. 
parviflora flavonoids in the SLNs and gel that had permeated 
through the skin after 25 h [(95.57依9.08) and (81.04依5.82) g, 
respectively] were found to be significantly different (P<0.05).
   Zhao J et al., 2009[41] prepared and evaluated brucine-
loaded polylacticacid nanoparticles (Bru-PLA-NPs). The Bru-
PLA-NPs were prepared by solvent diffusion method. The 
physical, chemical properties and in vitro release behavior of 
the prepared Bru-PLA-NPs were evaluated, respectively. The 
Bru-PLA-NPs prepared by solvent diffusion method exhibited 
small particle size, high Bru-loading efficiency, and obvious 
sustained release in vitro. The nanoparticle will increase the 
bioavailability and bioactivity of phytomedicine by reducing 
the size of the particles[42], surface modification[43], attaching 
or entrapping the phytomedicine with different polymers of 
micro or nano materials (Figure 7)[44,45]. The collection of recent 
advances of nanophytomedicne is listed in Table 1.
Figure 7. Nanophytomedicine enhances the bioavailability and bioactivity of 
phytomedicine.
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Table 1
Compilation of recent advances in nanophytomedicine.
Formulations Methods Active ingredients Purpose
Panax notoginsenoside-loaded core-shell 
hybrid liposomal vesicles
Water-in-oil-in-water double emulsion solvent 
evaporation method
Panax notoginsenoside
To increase the bioavailability and to enhance its 
protective effects
Celastrol nanoparticles
Poly (ethylene glycol)-block-poly (ε-caprolactone) 
nanopolymeric micelles
Celastrol To improve the hydrophilicity
Solid lipid nanoparticles High-pressure homogenization method
Frankincense and 
myrrh essential oils
To improve the hydrophilicity & bioavailability
Celastrol poly (ethylene glycol)-block-poly 
(ε-caprolactone) nanopolymeric micelles
Ultrasonic agitation using a sonic dismembrator followed 
by solvent evaporation
Celastrol To improve the hydrophilicity
Glyceryl monooleate nanoparticles High-pressure homogenization method Curcumin To enhance bioavailability in brain tissue
PEGylated nanoparticles Co-encapsulation
Ginkgolides A, B, C 
and bilobalide
Sustained and synchronized release of the four components
Pulmonary nanocrystal
Anti-solvent recrystallization followed by high pressure 
homogenization
Baicalein To enhance the bioavailability
Tanshinone IIA nanoemulsions Emulsification/high pressure homogenization Tanshinone IIA To improve the hydrophilicity & bioavailability
Curcumin in nanosuspensions Solvent evaporation method Curcumin To improve the hydrophilicity & bioavailability
Solid lipid nanoparticles Ultrasonic and high-pressure homogenization method Cryptotanshinone To improve the bioavailability
Solid lipid nanoparticles Oil-in-water microemulsion Kaempferia parviflora To enhance their transdermal permeability
Polylacticacid nanoparticles Solvent diffusion method Brucine Sustained release
Artemisinin nanocapsules Self assembly procedure Artemisinin To increase the biovailability
Taxel loaded nanoparticles Emulsion solvent evaporation method Taxel To increase the biovailability
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4. Conclusion
   Phytomedicine posses a significant therapeutic efficacy that 
should be explored with nanotechnology. Literatures reported 
that phytomedine posses excellent in-vitro bioactivity but 
poor aqueous solubility, larger molecular size, degradation 
during gastric emptying, extensive metabolism are the certain 
problems, which limits the utility of these plant extracts in-
vivo. Application of nanotechnology leads to increase in 
bioavailability and bioactivity of phytomedicine by reducing 
the size of the particles, surface modification, attaching or 
entrapping the phytomedicine with different polymers of micro 
or nano materials. Nanomaterials aids the targeted delivery, 
sustained delivery and improves the pharmacokinetics profile, 
diffusion of drugs into various organs by crossing the barriers 
including the blood brain barrier. The current research should 
focus on designing and development of multifunctional 
nanomaterials and in-vivo studies of their formulations.   
  
Conflict of interest statement
   We declare that we have no conflict of interest.
Acknowledgements
   The authors are thankful to the Research, Knowledge and 
Technology Transfer, Ambo University, Ambo, Ethiopia for 
the financial support, Grant No. AU/PHAR 54/2004 EC. The 
authors thank for the support and assistance of the Mrs. 
Vanapalli V Satya Veni, Lecturer, Department of Pharmacy, 
College of Medicine and Health Sciences, Ambo University, 
Ambo, Ethiopia.
Comments 
Background
   This is a review article summarising the purpose and 
methods used for the formulation of phytomedicines into 
nano-sized drug delivery systems. The review describes 
the general advantages of nanoformulation before outlining 
specific examples from the literature using plant-derived 
actives.
Research frontiers
   This review article is a useful summary of some recent 
studies in nanoformulation of phytomedicines.
Related reports
   It does cite general nanoformulation papers and specific 
phytoformulations highlighting the absence of significant 
literature attempting a review of nanoformulation of 
phytomedicines.
Innovations and breakthroughs
   The innovation is in bringing together a range of 
formulation techniques which can be applied to 
phytomedicines. It has a general introduction before 
highlighting some particular studies using a variety of 
actives and formulation strategies and summarising the 
results.
Applications
   This paper serves as a useful introduction to researchers 
without a background in pharmaceutical formulation of the 
wide range of different formulation strategies that can be 
applied to phytomedicines. Strategies to improve solubility 
and absorption are highlighted.   
 
Peer review
   This is a useful summary of a range of different formulation 
approaches that can be used to improve bioavailability. The 
authors have focused on a range of actives and this paper 
gives a welcome insight into how pharmaceutical formulation 
has been applied to overcome a number of challenges.
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